Home » Stocks » Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. (KPTI)

Stock Price: $14.62 USD -0.54 (-3.56%)
Updated Aug 14, 2020 12:20 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.07B
Revenue (ttm) 82.90M
Net Income (ttm) -189.37M
Shares Out 73.48M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $14.62
Previous Close $15.16
Change ($) -0.54
Change (%) -3.56%
Day's Open 15.13
Day's Range 14.57 - 15.34
Day's Volume 425,313
52-Week Range 8.02 - 29.61

More Stats

Market Cap 1.07B
Enterprise Value 902.74M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 73.48M
Float 44.15M
EPS (basic) -2.84
EPS (diluted) -2.84
FCF / Share -2.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 15.58M
Short Ratio 9.65
Short % of Float 22.30%
Beta 1.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.96
PB Ratio 8.41
Revenue 82.90M
Operating Income -170.34M
Net Income -189.37M
Free Cash Flow -161.47M
Net Cash 171.51M
Net Cash / Share 2.33
Gross Margin -101.15%
Operating Margin -205.49%
Profit Margin -228.40%
FCF Margin -194.78%
ROA -34.45%
ROE -178.43%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 8
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$32.00*
(118.88% upside)
Low
20.0
Current: $14.62
High
41.0
Target: 32.00
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue40.8930.341.610.150.250.230.390.630.15
Revenue Growth34.8%1790.09%942.21%-38.4%9.17%-40.83%-38.96%317.11%-
Gross Profit38.4930.341.610.150.250.230.390.630.15
Operating Income-189-180-131-111-119-75.85-33.95-15.89-10.31
Net Income-200-178-129-110-118-75.78-33.95-15.89-10.31
Shares Outstanding61.9656.8045.9037.5235.6231.146.071.781.00
Earnings Per Share-3.22-3.14-2.81-2.92-3.32-2.43-5.59-8.95-10.27
Operating Cash Flow-191-159-73.72-84.39-94.03-51.45-30.29-15.51-8.55
Capital Expenditures-0.21-2.36-0.06-0.07-1.42-2.83-0.06-0.12-0.38
Free Cash Flow-191-161-73.78-84.46-95.45-54.28-30.35-15.63-8.93
Cash & Equivalents2643291471301762061560.390.00
Total Debt125103-------
Net Cash / Debt1392261471301762061560.390.00
Assets2953411801802152201581.31-
Liabilities24515850.8318.1417.0813.543.2929.19-
Book Value49.77183129162198207155-27.88-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Karyopharm Therapeutics, Inc.
Country United States
Employees 347
CEO Michael G. Kauffman

Stock Information

Ticker Symbol KPTI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KPTI
IPO Date November 6, 2013

Description

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIOÂ), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.